Cargando…

The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF(V600E) Mutation

OBJECTIVE: To study the association between radioiodine refractory papillary thyroid carcinoma, sodium/iodide symporter (NIS) expression, and the BRAF(V600E) mutation. METHODS: A study was conducted on 30 radioiodine refractory papillary thyroid carcinoma patients and 30 radioiodine-avid papillary t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anekpuritanang, Tauangtham, Uataya, Maythad, Claimon, Apichaya, Laokulrath, Natthawadee, Pongsapich, Warut, Pithuksurachai, Paveena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254588/ https://www.ncbi.nlm.nih.gov/pubmed/34234465 http://dx.doi.org/10.2147/OTT.S308910

Ejemplares similares

Notch Intracellular Domain (NICD) Expression and Clinical Manifestations of Second Primary Tumor at Esophagus in Patients with Head and Neck Squamous Cell Carcinoma
por: Anekpuritanang, Tauangtham, et al.
Publicado: (2019)

CD8+ T Cells and PD-L1 Expression as Prognostic Indicators in a Low Prevalence of HPV-Associated Oropharyngeal Squamous Cell Carcinoma
por: Atipas, Kawita, et al.
Publicado: (2023)

Prevalence of HPV infection in hypopharyngeal and laryngeal squamous cell carcinoma at Thailand's largest tertiary referral center
por: Pongsapich, Warut, et al.
Publicado: (2017)

Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
por: Zhang, Honglai, et al.
Publicado: (2018)

Glycosylation of Sodium/Iodide Symporter (NIS) Regulates Its Membrane Translocation and Radioiodine Uptake
por: Chung, Taemoon, et al.
Publicado: (2015)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter
por: Huang, R, et al.
Publicado: (2011)

Induction of Sodium/Iodide Symporter (NIS) Expression and Radioiodine Uptake in Non-Thyroid Cancer Cells
por: Liu, Zhi, et al.
Publicado: (2012)

Extracellular vesicles deliver sodium iodide symporter protein and promote cancer cell radioiodine therapy
por: Lee, Jin Hee, et al.
Publicado: (2022)

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
por: Ge, Junshang, et al.
Publicado: (2020)

Dimerization of the Sodium/Iodide Symporter
por: Thompson, Rebecca J., et al.
Publicado: (2019)

Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib
por: Jafri, Sabih, et al.
Publicado: (2021)

The glial fibrillary acidic protein promoter directs sodium/iodide symporter gene expression for radioiodine therapy of malignant glioma
por: LI, WEI, et al.
Publicado: (2013)

Enhancement of Natural Killer Cell Cytotoxicity by Sodium/Iodide Symporter Gene-Mediated Radioiodine Pretreatment in Breast Cancer Cells
por: Kim, Hae Won, et al.
Publicado: (2013)

A Steep Radioiodine Dose Response Scalable to Humans in Sodium Iodide Symporter (NIS) Mediated Radiovirotherapy for Prostate Cancer
por: Trujillo, Miguel A., et al.
Publicado: (2012)

Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine
por: Hutzen, Brian, et al.
Publicado: (2012)

Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer
por: Plantinga, Theo S., et al.
Publicado: (2016)

B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1
por: Choi, Yong Won, et al.
Publicado: (2014)

Sodium iodide symporter-targeted gene therapy in glioblastoma
por: Nicola, Juan Pablo, et al.
Publicado: (2023)

Radioiodine therapy for castration-resistant prostate cancer following prostate-specific membrane antigen promoter-mediated transfer of the human sodium iodide symporter
por: Gao, Xiao-Feng, et al.
Publicado: (2014)

Combined 2-deoxy glucose and metformin improves therapeutic efficacy of sodium-iodide symporter-mediated targeted radioiodine therapy in breast cancer cells
por: Chatterjee, Sushmita, et al.
Publicado: (2015)

Propensity Score-Matched Analysis to Identify Pathways Associated with Loss of Sodium Iodide Symporter in Papillary Thyroid Cancer
por: Lee, Fang, et al.
Publicado: (2022)

Clinical significance of the BRAF(V600E) mutation in PTC and its effect on radioiodine therapy
por: Zhu, Guoquan, et al.
Publicado: (2019)

Tumor microenvironment affects exogenous sodium/iodide symporter expression
por: Castillo-Rivera, Fabio, et al.
Publicado: (2020)

(18)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography for preoperative planning in a rare case of hyperfunctional bilateral adrenocortical carcinoma and review of literatures
por: Claimon, Apichaya, et al.
Publicado: (2020)

BRAF mutation in cytologically indeterminate thyroid nodules: after reclassification of a variant thyroid carcinoma
por: Pongsapich, Warut, et al.
Publicado: (2019)

An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na(+)/I(−) Symporter Function in Radioiodine-Refractory Papillary Thyroid Cancer Cells
por: Singh, Thoudam Debraj, et al.
Publicado: (2023)

Decreased Expression of Thyroglobulin and Sodium Iodide Symporter Genes in Hashimoto's Thyroiditis
por: Popławska-Kita, Anna, et al.
Publicado: (2014)

Physiological sodium concentrations enhance the iodide affinity of the Na(+)/I(−) symporter
por: Nicola, Juan P., et al.
Publicado: (2014)

Overexpression of Both Human Sodium Iodide Symporter (NIS) and BRG1-Bromodomain Synergistically Enhances Radioiodine Sensitivity by Stabilizing p53 through NPM1 Expression
por: Na, Juri, et al.
Publicado: (2023)

The BRAF(V600E) mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy?
por: Shen, Guohua, et al.
Publicado: (2019)

Conserved charged amino acid residues in the extracellular region of sodium/iodide symporter are critical for iodide transport activity
por: Li, Chia-Cheng, et al.
Publicado: (2010)

Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer
por: Micali, Salvatore, et al.
Publicado: (2014)

In Vivo Myoblasts Tracking Using the Sodium Iodide Symporter Gene Expression in Dogs
por: Punzón, Isabel, et al.
Publicado: (2020)

Targeting non-canonical pathways as a strategy to modulate the sodium iodide symporter
por: Read, Martin L., et al.
Publicado: (2022)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

BRAF V600E and lymph node metastases in papillary thyroid cancer
por: Chen, Pan, et al.
Publicado: (2020)

The Sodium Iodide Symporter (NIS) as an Imaging Reporter for Gene, Viral, and Cell-based Therapies
por: Penheiter, Alan R, et al.
Publicado: (2012)

Resveratrol Inhibits Sodium/Iodide Symporter Gene Expression and Function in Rat Thyroid Cells
por: Giuliani, Cesidio, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6viusmjrs3jkvq9u26ch8hakc9